Role of Cytokines

  • Manzoor M. KhanEmail author


Cytokines are small glycoproteins produced by a number of cell types, predominantly leukocytes, that regulate immunity, inflammation and hematopoiesis. They regulate a number of physiological and pathological functions including innate immunity, acquired immunity and a plethora of inflammatory responses. The discovery of cytokines was initiated in the 1950s, but the precise identification of their structure and function took many years. The original discoveries were those of IL-I, IFN and nerve growth factors (NGFs); however, these cytokines were purified and given their names years later. Elucidation of the precise physiological, pathological and pharmacological effects of some of the cytokines is still in progress. The modern techniques of molecular biology were principally responsible for their complete identification and as a consequence, several hundred cytokine proteins and genes have been identified, and the process still continues.

Cytokines are produced from...


Mast Cell Idiopathic Pulmonary Fibrosis Mononuclear Phagocyte Hairy Cell Leukemia Capillary Leak Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Arend WP, Dayer JM. 1990. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheumat. 33:305–315.PubMedCrossRefGoogle Scholar
  2. Asadullah K, Sterry W, Volk HD. 2003. Interleukin-10 therapy – Review of a new approach. Pharmacol Rev. 55:241–269.PubMedCrossRefGoogle Scholar
  3. Atkins MB. 2002. Interleukin-2: Clinical applications. Semin Oncol. 29:12–17.PubMedCrossRefGoogle Scholar
  4. Auron PE, Webb AC, Rosenwassser LJ, Mucci SF, et al. 1984. Nucleotide sequence of human monocyte interleukin 1 precursor CDA. Proc Nat Acad Sci USA. 81:7907–7911.Google Scholar
  5. Becknell B, Caligiuri MA. 2005. Interleukin 2 and interleukin 15, and their roles in human natural killer cells. Adv Immunol. 86:209–239.PubMedCrossRefGoogle Scholar
  6. Bhatia M, Davenport V, Cairo MS. 2007. The role of interleukin-11 to prevent chemotherapy-induced cytopenia in patients with solid tumors, lymphomas, acute myeloid leukemia and bone marrow failure syndromes. Leuk Lymph. 48:9–15.CrossRefGoogle Scholar
  7. Bouchner BS, Klunk DA, Sterbinsky SA, Coffman RL, et al. 1995. IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells.J Immuno. 154:799–803.Google Scholar
  8. Bradding P, Roberts JA, Britten KM, Montefort S, et al. 1994. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: Evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol. 10:471–480.PubMedGoogle Scholar
  9. Buetler B, Greenwald D, Hulmes JD, Chang M, et al. 1985. Identity of tumor necrosis factor and the macrophage-secreted factor cachectin. Nature. 316:552–554.CrossRefGoogle Scholar
  10. Charo IF, Romsohoff RM. 2006. The many roles of chemokines and chemokines receptors in inflammation. NEJM. 354:610–621.PubMedCrossRefGoogle Scholar
  11. Colotta F, Dower SK, Sims JE, Mantovani A. 1994. The type II “decoy” receptor: A novel regulatory pathway for interleukin-1. Immunol Today. 15:562–566.PubMedCrossRefGoogle Scholar
  12. Dinarello CA. 1984. Interleukin-1 and the pathogenesis of acute phase response. NEJM. 311:1413–1418.PubMedCrossRefGoogle Scholar
  13. Dinarello CA. 1998. The interleukin-1 family: 10 years of discovery. FASEB J. 8:1314–25.Google Scholar
  14. Dinarello CA. 2000. The role of interleukin-1 receptor antagonist in blocking inflammation mediated by IL-1. NEJM. 343:732–734.PubMedCrossRefGoogle Scholar
  15. Dinarello CA. 2002. The IL-1 family and inflammatory disease. Clin Exp Rheumatol. 20:S1–S13..PubMedGoogle Scholar
  16. Dinarello CA. 2005. Blocking IL-1 in systemic inflammation. J Exp Med. 201:1355–1359.PubMedCrossRefGoogle Scholar
  17. Du XX, Williams DA. 1994. Interleukin 11: A multifunctional growth factor derived from the hematopoietic microenvironment. Blood. 83:2023–2030.PubMedGoogle Scholar
  18. Dubucquoi S, Desreumaux P, Janin A, Klein O, et al. 1994. Interleukin 5 synthesis by eosinophils: Association with granules and immunoglobulin-dependent secretion. J Exp Med. 179:703–708.PubMedCrossRefGoogle Scholar
  19. Fernandez E, Lolis E. 2002. Structure, function and inhibition of chemokines. Ann Rev Pharmacol Toxicol. 42:469–499.CrossRefGoogle Scholar
  20. Flier J, Boorsma DM, Van Beek PJ, Niboer C, et al. 2001. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol. 194:398–405.PubMedCrossRefGoogle Scholar
  21. Gaffen SL, Liu KD. 2004. Overview of interleukin-2 function, production and clinical applications. Cytokine. 28:109–123.PubMedCrossRefGoogle Scholar
  22. Gerard C, Rollins BJ. 2001. Chemokines and disease. Nat Immunol. 2:108–115.PubMedCrossRefGoogle Scholar
  23. Gracie JA, Robertson SE, McInnes IB. 2003. Interleukin-18. J Leukocyte Biol. 73:213–224.PubMedCrossRefGoogle Scholar
  24. Grande C, Firvida JL, Navas V, Casal J. 2006. Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma. Anticancer Drugs. 17:1–12.PubMedCrossRefGoogle Scholar
  25. Gray PW, Goeddel DV. 1982. Structure of the human interferon gene. Nature. 298:859–863.PubMedCrossRefGoogle Scholar
  26. Horuk R. 1999. chemokine receptors and HIV-1. Immunol Today. 20:89–94.PubMedCrossRefGoogle Scholar
  27. Howard M, Paul WE. 1982. Interleukins for B lymphocytes. Lymphokine Res. 1:1–4.PubMedGoogle Scholar
  28. Ihle JN. 1995. Cytokine receptor signaling. Nature. 377:591–594.PubMedCrossRefGoogle Scholar
  29. Ihle JN, Witthun BA, Quelle FW, Yamamoto K, et al. 1995. Signaling through the hematopoietic cytokine receptors. Ann Rev Immunol. 13:369–398.CrossRefGoogle Scholar
  30. Isaacs A, Lindermann J. 1957. Virus interference. I. The interferon. Proc Roy Soc Lond Biol Sci. 147:258–267.Google Scholar
  31. Issac C, Robert NJ, Bailey FA, Schuster MW, et al. 1997. Randomized placebo-controlled study of recombinant human interleukin 11 to prevent chemotherapy induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol. 15:3368–3377.Google Scholar
  32. Kaczmarski RS, Mufti GJ. 1993. Low-dose filgrastim therapy for chronic neutropenia. NEJM. 329:1280–1281.PubMedCrossRefGoogle Scholar
  33. Kaczmarski RS, Pazniak A, Lakhani A, Harvey E, Mufti GJ. 1993. A pilot study of low-dose recombinant human granulocyte-macrophage colony-stimulating factor in chronic neutropenia. Br J Hematol. 84:338–340.CrossRefGoogle Scholar
  34. Kaminuma O, Mori A, Kitamura N, Hashimoto T, et al. 2005. Role of GAGA-3 in IL-5 gene transcription by CD4+ T cells of asthmatic patients. Int Arch All Immunol. 137:55–59.CrossRefGoogle Scholar
  35. Kishimoto T, Akira S, Narazaki M, Taga T. 1995. Interleukin-6 family of cytokines. Blood. 86:1243–1254.PubMedGoogle Scholar
  36. Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, et al. 2005. Sargramostim for active Crohn’s disease. NEJM. 352:2193–2201.PubMedCrossRefGoogle Scholar
  37. Laing K, Secombes C. 2004. Chemokines. Dev Comp Immunol. 28:443–460.PubMedCrossRefGoogle Scholar
  38. Larsen CM, Faulenbach M, Vaag A, Velund A, et al. 2007. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. NEJM. 356:1517–1526.PubMedCrossRefGoogle Scholar
  39. Lee JS, Campbell HD, Kozak CA, Young IG. 1989. The IL-4 and IL-5 genes are closely linked and are part of a cytokine gene cluster on mouse chromosome 11. Somat Cell Mol Genet. 15:143–152.PubMedCrossRefGoogle Scholar
  40. Leischke GJ, Burgess AW. 1992. Granulocyte colony stimulating factor and granulocyte-macrophage colony stimulating factor. NEJM. 327:28–35.CrossRefGoogle Scholar
  41. Locksley RM, Killeen N, Lenardo MJ. 2001. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell. 104:487–501.PubMedCrossRefGoogle Scholar
  42. Lotz MT, Matory YL, Rayner AA. 1986. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer. 58:2764–2772.CrossRefGoogle Scholar
  43. Louahed J, Kermouni A, Van Snick J, Renauld JC. 1995. IL-9 induces expression of granzymes and high affinity IgE receptor in murine T helper clones. J Immunol. 154:5061–5070.PubMedGoogle Scholar
  44. Louahed J, Toda M, Jen J, Hamid Q, et al. 2000. Interleukin-9 upregulates mucus expression in the airways. Am J Resp Cell Mol Biol. 22:649–656.Google Scholar
  45. Louahed J, Zhou Y, Maloy WL, Rani PU, et al. 2001. Interleukin 9 promotes influx and local maturation of eosinophils. Blood. 97:1035–1042.PubMedCrossRefGoogle Scholar
  46. Ma A, Koka R, Burkett P. 2006. Diverse functions of IL-2, IL-15 and IL-7 in lymphoid homeostasis. Ann Rev Immunol. 24:657–679.CrossRefGoogle Scholar
  47. Malozowski S, Sahlroot JT, Mandruup-Poulsen T, Seifert B, et al. 2007. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. NEJM. 357:302–303.PubMedCrossRefGoogle Scholar
  48. Massa M, Rosti V, Ferrario M, Campanelli R, et al. 2005. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood. 105:199–206.PubMedCrossRefGoogle Scholar
  49. McDermott DF. 1007. Update on the application of interleukin 2 in the treatment of renal cell carcinoma. Clin Can Res. 13:716S–720S..Google Scholar
  50. Mentink MM, Wynn TA. 2004. Opposing roles for IL-13 and IL-13 receptor alpha 2 in health and disease. Immunol Rev. 202:191–202.CrossRefGoogle Scholar
  51. Milburn MV, Hassell AM, Lambert MH, Jordan SR, et al. 1993. A novel dimer configuration revealed by the crystal structure at 2.4A resolution of human initerleukin-5. Nature. 363:172–176.PubMedCrossRefGoogle Scholar
  52. Mocellin S, Panelli MC, Wang E, Nagorsen D, et al. 2003. The dual role of IL-10. Trends Immunol. 4:36–43.CrossRefGoogle Scholar
  53. Moore KW, de-Waal R, Coffman RL, O’Garra A. 2001. Interleukin-10 and the interleukin-10 receptor. Ann Rev Immunol. 19:683–765.CrossRefGoogle Scholar
  54. Morstyn G, Campbell L, Souza LM, Alton NK, et al. 1988. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet. 1:667–672.PubMedCrossRefGoogle Scholar
  55. Murdoch C, Finn A. 2001. Chemokine receptors and the role in inflammation and infectious disease. J Am Soc Hematol. 95:3032–3043.Google Scholar
  56. Murphy PM, International Union of Pharmacology. 2002. Update on chemokine receptor nomenclature. Pharmacol Rev. 54:227–229.Google Scholar
  57. Murray PJ. 2006. Understanding and exploiting the endogenous interleukin 10/STAT3-mediated anti-inflammatory response. Curr Opin Pharmacol. 6:379–386.PubMedCrossRefGoogle Scholar
  58. Nagata S, Tsuchiya M, Asano S, Kaziro Y, et al. 1986. Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature. 319:415–418.PubMedCrossRefGoogle Scholar
  59. Negrin RS, Haeuber DH, Nagler A, Kobayashi Y, et al. 1990. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte-colony stimulating factor. Blood. 76:36–43.PubMedGoogle Scholar
  60. Nelson, BH. 2002. Interleukin-2 signaling and the maintenance of self tolerance. Curr Dire Autoimm. 5:92–112.CrossRefGoogle Scholar
  61. Nicolaides NC, Holroyd KJ, Ewart SL, Eleff SM, et al. 1997. Interleukin-9: A Candidate gene for asthma. Proc Nat Acad Sci USA. 94:13175–13180.Google Scholar
  62. Novick D, Kim SH, Fantuzzi G, Rezinkov L, et al. 1999. Interleukin-18 binding protein: A novel modulator of TH1 cytokine response. Immunity. 10:127–136.PubMedCrossRefGoogle Scholar
  63. Ohki Y, Heissig B, Sato Y, Akiyama H, et al. 2005. Granulocyte colony stimulating factor promotes neovascularization by releasing vascular endothelial growth factor from neutrophils. FASEB J. 19:2005–2007.PubMedGoogle Scholar
  64. Old LJ. 1985. Tumor necrosis factor. Science. 230:630–632.PubMedCrossRefGoogle Scholar
  65. Pau AK, Tavel JA. 2002. Therapeutic use of interleukin-2 in HIV-infected patients. Curr Opin Pharmacol. 2:433–439.PubMedCrossRefGoogle Scholar
  66. Pestkoi S, Krause CD, Sarkar D, Walter MR. 2004. Interleukin-10 and related cytokines and receptors. Ann Rev Immunol. 22:929–979.CrossRefGoogle Scholar
  67. Pilette C, Ouadrhiri Y, Van Snick J, Renauld JC, et al. 2002. Interleukin-9 inhibits oxidative burst in LPS-stimulated human blood monocytes through TGF-β. J Immunol. 168:4103–4111.PubMedGoogle Scholar
  68. Pizarro TT, Cominelli F. 2007. Cloning of IL-1 and the birth of a new era in cytokine biology. J Immunol. 178:5411–5412.PubMedGoogle Scholar
  69. Renauld JC, Houssiau F, Druez C, Uyttenhove C, et al. 1993. Interleukin-9. Int Rev Exp Path. 34:99–109.PubMedGoogle Scholar
  70. Renauld JC, Vink A, Louahed J, VanSnick J. 1995. Interleukin-9 is a major anti-apoptotic factor for thymic lymphomas. Blood. 85:1300–1305.PubMedGoogle Scholar
  71. Sanderson CJ. 1992. Interleukin-5, eosinophils and disease. Blood. 79:3101–3109.PubMedGoogle Scholar
  72. Schroder K, Hertzog PJ, Ravasi T, Hume DA. 2003. Interferon-γ, an overview of signals, mechanisms and functions. J Leukocyte Biol. 75:163–189.PubMedCrossRefGoogle Scholar
  73. Scott DL, Kingsley GH. 2006. Tumor necrosis factor inhibitors for rheumatoid arthritis. NEJM. 355:704–712.PubMedCrossRefGoogle Scholar
  74. Sen GC. 2003. Viruses and interferons. Ann Rev Microbiol. 55:255–281.CrossRefGoogle Scholar
  75. Shen HH, Ochkur SI, McGarry MP, Crosby JR, et al. 2003. A causative relationship exists between eosinophils and the development of allergic pulmonary pathologies in the mouse. J Immunol. 170:3296–3305.PubMedGoogle Scholar
  76. Smith, KA, Gilbride KJ, Favata MF. 1980. Lymphocyte activating factor promotes T-cell growth factor production by cloned murine lymphoma cells. Nature. 287:853–855.PubMedCrossRefGoogle Scholar
  77. Taniguchi T, Matsui H, Fujita T, Kakaoka C. 1983. Structure and expression of a cloned cDNA for human interleukin-2. Nature. 302:205–310.CrossRefGoogle Scholar
  78. Taniguchi T, Takaoka A. 2002. The interferon-alpha/beta system in antiviral responses: A multimodal machinery of gene regulation by the IRF family of transcription factors. Curr Opin Immunol. 14:111–116.PubMedCrossRefGoogle Scholar
  79. Temesgen Z. 2006. Interleukin-2 for the treatment of human immunodeficiency virus. Drugs Today. 42:791–801.PubMedCrossRefGoogle Scholar
  80. Tepler I, Elias L, Smith JW, Hussein M, et al. 1996. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood. 87:3607–3614.PubMedGoogle Scholar
  81. Trebst C, Sorensen TL, Kivisakk P, Cathcart MK, et al. 2001. CCR1+/CCR5+ mononuclear phagocyte accumulate in the central nervous system of patients with multiple sclerosis. Am J Pathol. 159:1701–1710.PubMedCrossRefGoogle Scholar
  82. Valgimigli M, Rigolin GM, Cittani C, Malagutti P, et al. 2005. Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans. Eur Heart J. 26:1838–1845.PubMedCrossRefGoogle Scholar
  83. Van Damme J, De Ley M, Opdenakker G, Billiau A, et al. 1985. Homogenous interferon-inducing 22 K factor is related to endogenous pyrogen and interleukin-1. Nature. 314:266–268.PubMedCrossRefGoogle Scholar
  84. Van Leeuwen BH, Martinson ME, Webb GC, Young IG. 1989. Molecular organization of the cytokine gene cluster, involving the human IL-3, IL-4, IL-5 and GM-CSF genes, on human chromosome 5. Blood. 73:1142–1148.PubMedGoogle Scholar
  85. Waldmann TA. 2006. The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat Rev Immunol. 6:595–601.PubMedCrossRefGoogle Scholar
  86. Walter MR, Cook, WJ, Zhao BG, Cameron RP, et al. 1992. Crystal structure of recombinant human interleukin-4. J Biol Chem. 267:20371–20376.PubMedGoogle Scholar
  87. Weaver CH, Schulman KA, Wilson-Relyea B, Birch R, et al. 2000. Randomized trial of Filgrastim, Sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral blood stem cells. J Clin Oncol. 18:43–53.PubMedGoogle Scholar
  88. Wills-Karp M, Luyiambazi J, Xu X, Schofield B, et al. 1998. Interleukin-13: Central mediator of allergic asthma. Science. 282:2258–2261.PubMedCrossRefGoogle Scholar
  89. Wynn TA. 2003. IL-13 effector functions. Ann Rev Immunol. 21:425–456.CrossRefGoogle Scholar
  90. Yokota T, Otsuka K, Mosmann T, Banchereau J, et al. 1986. Isolation and characterization of a human interleukin cDNA clone, homologous to mouse B-cell stimulatory factor 1, that expresses B-cell and T-cell stimulating activities. Proc Nat Acad Sci USA. 83:5894–5898.Google Scholar
  91. Zdanov A. 2004. Structural features of the interleukin-10 family of cytokines. Curr Pharm Design. 10-:3873–3884..CrossRefGoogle Scholar
  92. Zheng LM, Ojcius DM, Garaud F, Roth C, et al. 1996. Interleukin-10 inhibits tumor metastasis through an NK cell dependent mechanism. J Exp Med. 184:579–584.PubMedCrossRefGoogle Scholar
  93. Zhou Y, McLane M, Levitt RC. 2001. TH2 cytokines and asthma: Interleukin 9 as therapeutic target for asthma. Resp Res. 2:80–84.CrossRefGoogle Scholar
  94. Zimmermann N, Hershey GK, Foster PS, Rothenberg ME. 2003. Chemokines in asthma: Cooperative interaction between chemokine and IL-13. J All Clin Immunol. 111:227–242.CrossRefGoogle Scholar
  95. Zohlnhofer D, Ott I, Mehilli J, Schoming K, et al. 2006. Stem cell mobilization by granulocyte-colony-stimulating factor in patients with acute myocardial infarction. JAMA. 295: 1003–1010.PubMedCrossRefGoogle Scholar
  96. Zurawski G, de Vries JE. 1994. Interleukin 13, an interleukin-4 like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today. 15:19–26.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Creighton University Medical CenterOmahaUSA

Personalised recommendations